Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Completes Acquisition of Gen-Probe

NEW YORK (GenomeWeb News) – Hologic has completed its $3.8 billion acquisition of Gen-Probe following approval from Gen-Probe's shareholders yesterday.

Gen-Probe will now become a wholly owned subsidiary of Hologic. Carl Hull, the chairman and CEO of Gen-Probe, will stay with Hologic for at least 15 months to direct the combined diagnostic operations, as the firms previously announced.

Hologic signed the agreement in April to acquire Gen-Probe for $82.75 per share. The firm reiterated today that it expects the deal to be $.20 accretive to its non-GAAP adjusted earnings per share in fiscal 2013. It also said that the combined firm expects to realize around $75 million in cost synergies within three years following closure of the transaction.

As of today, Gen-Probe's shares have ceased trading on the Nasdaq.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.